Atorvastatin treatment decreases inflammatory and proteolytic activity in patients with hypercholesterolemia

Kardiologia Polska

Volumn 60, Issue 5, 2004, Pages 454-458

  Ercan, Ertugrul ^a   Tengiz, Istemihan ^a   Altuglu, Imre ^b   Sekuri, Cevat ^c   Aliyev, Emil ^a   Ercan, H Ekin ^a   Akin, Mustafa ^b  

^a Central Hospital Izmir   (Turkey)

^b EGE UNIVERSITY   (Turkey)

^c CELAL BAYAR UNIVERSITY   (Turkey)

Author keywords

C reactive protein; Hypercholesterolemia; Inflammation; Mmp 9; Statins

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; GELATINASE B; LOW DENSITY LIPOPROTEIN; STATINE DERIVATIVE;

ADULT; ANTIINFLAMMATORY ACTIVITY; ANTIPLATELET ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DRUG ACTIVITY; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; INTERMETHOD COMPARISON; MALE; PROSPECTIVE STUDY; PROTEIN DEGRADATION; RANDOMIZED CONTROLLED TRIAL;

EID: 2642545963     PISSN: 00229032     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Downs J.R., Clearfield M., Weis S. et al. for AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 1998, 279, 1615-1622.
2. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial Results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984, 251, 365-374.
3. Saren P., Welgus H.G., Kovanen P.T.: TNF alfa and IL-1 beta selectively induce expression of 92-kDa gelatinase by human macrophages. J. Immunol. 1996, 157, 4159-4165.
4. Dollery C., McEwan J., Henney A.: Matrix metalloproteinases and cardiovascular disease. Circ. Res. 1995, 77, 863-868.
5. Birkedal-Hansen H., Moore W., Bodden M.K. et al.: Matrix metalloproteinases: a review. Crit. Rev. Oral. Biol. Med. 1993, 4, 197-250. MMP-kontrol.
6. Neumann F., Ott I., Gawaz M. et al.: Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. Circulation 92 (4), 748-767.
7. Entman M.L., Ballantyne CM.: Inflammation in acute coronary syndromes. Circulation 88 (2), 1993, 800-803.
8. Hansson G.K.: Immune mechanisms in atherosclerosis. Arterioscscler. Thromb. Vasc. Biol. 2001, 21 (2), 1876-1890.
9. Freestone T., Turner R.J., Coady A. et al.: Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm. Arterioscscler. Thromb. Vasc. Biol. 1995, 15 (8), 1145-1151.
10. Dollery C.M., McEwan J.R., Henney A.M.: Matrix metalloproteinases and cardiovascular disease 1995, 77 (5), 863-868.
11. Ries C., Petrides P.E.: Cytokine regulation of matrix metalloproteinase activity and its regulator dysfunction in disease. Biol. Chem. 1995, 376, 345-355.
12. Riesen W.F., Engler H., Risch M. et al.: Short term effects of atorvastatin on C-reactive protein. Eur. Heart J. 2002, 23, 794-799.
13. van de Ree M.A., Huisman M.V., Princen H.M. et al.: Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis 2003, 166 (1), 129-35.
14. Olsson A.G., Schwartz G.G., Jonasson L. et al.: Are early clinical effects of cholesterol lowering mediated through effects on inflammation? Acta Physiol. Scand. 2002, 176 (2), 147-50.
15. Wiklund O., Mattsson-Hulten L., Hurt-Camejo E. et al.: Effects of simvastatin and atorvastatin on inflammation markers in plasma. J. Intern. Med. 2002, 251 (4), 338-47.
16. Plenge J.K., Hernandez T.L., Weil K.M. et al.: Simvastatin lowers C-reactive protein within 14 days. Circulation 2002, 106, 1447-1452.
17. Rezaie-Majd A., Maca T., Bucek R.A. et al.: Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler. Thromb. Vasc. Biol. 2002, 1, 22 (7), 1194-9.
18. Nagashima H., Aoka Y., Sakomura Y. et al.: 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, cerivastatin, suppresses production of matrix metalloproteinase-9 in human abdominal aortic aneurysm wall. J. Vasc. Surg. 2002, 36 (1), 158-63.
19. Bellosta S., Via D., Canavesi M. et al.: HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler. Thromb. Vasc. Biol. 1998, 18 (11), 1671-8.
20. Brown D.L., Hibbs M.S., Kearney M. et al.: Identification of 92 kD gelatinase in human coronary atherosclerotic lesions: Association of active enzyme synthesis with unstable angina. Circulation 1995, 91, 2125-2131.
21. Fuster V.: The vulnerable atherosclerotic plaque: understanding, identification, and modification. 2001, Futura Publishing Company, Inc. Armonk NY. Chapter 22: regulation of metalloproteinases and their inhibitors in atheroma.
22. Matrisian L.M. Metalloproteinases and their inhibitors in matrix remodelling. Trends Genet. 1990, 6, 121-125.
23. Gallin J.I., Synderman R. Inflammation: Basic principles and clinical correlates. Chapter 16. Fibroblasts and matrix proteins. 3rd. ed. Lippincott Williams&Wilkins, Philadelphia 1999, 227-257.
24. Shah P.K., Falk E., Badimon J.J. et al.: Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques: potential role of matrix matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 1995, 92 (6), 1565-1569.
25. Galis Z.S., Sukhova G.K., Kranzhover R. et al.: Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc. Natl. Acad. Sci. USA. 1995, 92, 402-406.
26. Kai H., Ikeda H., Yasukawa H. et al.: Peripheral blood levels of matrix metalloproteinases-2 and -9 are elevated in patients with acute coronary syndromes. J. Am. Coll. Cardiol. 1998, 32, 368-372.
27. Loftus I.M., Naylor A.R., Bell P.R.F., Thompson M.M.: Matrix metalloproteinases and atherosclerotic plaque instability. Br. J. Surg. 2002, 89 (6), 680-694.
28. Galis Z.S., Suhkova G.K., Lark M.W. et al.: Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest. 1994, 94, 2493-2503.
29. Inokubo Y., Hanada H., Ishizaka H. et al.: Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am. Heart J. 2001, 141, 211-217.
30. Zaltsman A., Newby A.: Increased secretion of geletinases A and B from the aortas of cholesterol fed rabbits: Relationship to lesion severity. Atherosclerosis 1997, 130, 61-70.
31. Chase A.J., Bond M., Crook M.F. et al.: Role of nuclear factor-kb activation in metalloproteinase-1, -3, and -9 secretion by human macrophages in vitro and rabbit foam cells produced in vivo. Arterioscler. Thromb. Vasc. Biol. 2002, 22, 765-771.
32. Rajavashists T.B., Xu X.P., Jovinge S. et al.: Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques: evidence for activation by proinflammatory mediators. Circulation 1999, 99 (24), 3103-3109.
33. Koh K.K., Son J.W., Ahn J.Y. et al.: Comparative effects of diet and statin on NO bioactivity and matrix metalloproteinases in hypercholesterolemic patients with coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 2002, 22, 19-23.
34. Masanori A., Elena R., Yoshikatsu O. et al.: Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation 1998, 97, 2433-2444.
35. Fukumoto Y., Libby P., Rabkin E. et al.: Statins alter smooth muscle cell accumulation and collagen content in established atheroma of Watanabe heritable hyperlipidemic rabbits. Circulation 2001, 20, 103 (7), 993-9.